Who Paid My Doc
Adam Rizvi
Neurocritical Care Riverside, CA Medical Doctor
NPI 1841551355 CMS profile 6692198
4234 Riverwalk Pkwy Ste 230, Riverside, CA 92505
General payments
$130
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Adam Rizvi of Riverside, CA is reported in the CMS Open Payments database as having received $130 across 3 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 31st percentile of Neurocritical Care profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $103 | 2 | |
| 2022 | General | $27 | 1 |
Beside peers
- Adam Rizvi
- Neurocritical Care median
- Middle half of Neurocritical Care
- National median
In program year 2025, general payments to Adam Rizvi were reported at $103. Among 223 Neurocritical Care profiles paid that year, the median was $98 and the middle half received between $34 and $262.
Show as a table
| Year | Adam Rizvi | Neurocritical Care median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $125 | $47–$286 | $163 |
| 2020 | $0 | $74 | $21–$153 | $114 |
| 2021 | $0 | $108 | $34–$250 | $132 |
| 2022 | $27 | $115 | $31–$277 | $149 |
| 2023 | $0 | $127 | $35–$275 | $160 |
| 2024 | $0 | $127 | $44–$265 | $164 |
| 2025 | $103 | $98 | $34–$262 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 16 billing codesPaid by Medicare
$42,577
Medicare patients
169
Services billed
275
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 68% | |
| Heart failure | 66% | |
| Diabetes | 62% | |
| Chronic kidney disease | 57% | |
| Arthritis | 56% | |
| Atrial fibrillation | 47% | |
| COPD | 37% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurocritical Care in California
Nerses Sanossian
Neurocritical Care · Los Angeles, CA
May Kim-Tenser
Neurocritical Care · Los Angeles, CA
Wengui Yu
Neurocritical Care · Orange, CA
Marion Buckwalter
Neurocritical Care · Stanford, CA
Johannes Pulst-Korenberg
Neurocritical Care · Los Angeles, CA
Arash Afshinnik
Neurocritical Care · Fresno, CA
Related records
Neurocritical Care in California
Practitioners in the same specialty and state, ranked by reported value.
All Neurocritical Care
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.